Efficacy of Guanxinning tablet in conjunction with recombinant human brain natriuretic peptide for patients diagnosed with acute ST segment elevation myocardial infarction
Objective To evaluate the therapeutic efficacy of Guanxinning tablet combined with recombinant human brain na-triuretic peptide for patients with acute ST segment elevation myocardial infarction(STEMI).Methods A total of 80 patients with STEMI treated at Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine from October 2021 to October 2023 were selected as the research subjects and divided into the control group(n=40)and the observation group(n=40)by random number table method.The patients in the control group received treatment with recombinant human brain natriuretic peptid while those in the obser-vation group received treatment of the combination of Guanxinning tablet and recombinant human brain natriuretic peptide.The total efficiency,myocardial markers,cardiac function,endothelial function and incidence of major adverse cardiovascular events(MACE)were compared between the two groups.Results The effective rate was higher in observation group than in control group(95.00%(38/40)vs 77.50%(31/40))(χ2=5.165,P=0.023).After one month,the levels of serum cardiac troponin I(cTnI)and creatine kinase myocardial isoenzyme(CK-MB)in the observation group and control group were(0.24±0.03)μg·L-1,(22.39±3.12)U·L-1 and(0.51±0.12)μg·L-1,(30.07±3.86)U·L-1,respectively,which were lower than those before the treatment((1.42±0.26)μg·L-1,(36.27±4.44)U·L-1,(1.45±0.27)μg·L-1,(36.02±4.41)U·L-1,respectively).Furthermore,the concentrations of cTnI and CK-MB in the observation group were lower in comparison to those in the control group(P＜0.05).The levels of LVESD and LVEDD in the observation group and control group were(37.05±4.32)mm,(43.33±5.27)mm,(42.15±4.82)mm,and(47.02±5.46)mm,respec-tively,which were lower than those before the treatment((48.31±5.59)mm,(48.25±5.57)mm,(53.17±6.21)mm and(53.49±6.24)mm,respectively),and they were significantly lower in observation group than in control group(P＜0.05).The level of LVEF in the observation group and control group was(55.67±6.45)%and(45.37±5.78)%,respectively,which were higher than those be-fore the treatment((39.12±5.03)%and(39.37±5.06)%,respectively),and it was significnatly higher in the observation group than in the control(P＜0.05).The levels of serum endothelin-1(ET-1)and vascular endothelial growth factor(VEGF)in the observation group and control group were(74.13±8.24)ng·L-1,(245.38±18.69)pg·L-1,(82.08±9.16)ng·L-1,(316.25±27.14)pg·L-1,respective-ly,which were lower than thsoe before the treatment((93.47±10.36)ng·L-1,(448.91±32.62)pg·L-1,(93.15±10.21)ng·L-1,(449.26±32.65)pg·L-1,respectively),and they were remarkably lower in observation group than that in control group(P＜0.05).The serum lev-el of NO in the observation group was(61.07±7.24)μmol·L-1 and in the control group was(54.62±6.1)μmol·L-1,which was higher than that before the treatment((41.36±5.33)μmol·L-1 and(41.02±5.27)μmol·L-1).Furthermore,the serum level of NO was markedly higher inobservation group than that in control group(P＜0.05).The incidence rate of MACE within the observation group(7.50%)was found to be lower compared to the control group(25.00%)(χ2=4.501,P=0.034).Conclusion Guanxinning tablet combined with recombinant human brain natriuretic peptide has good clinical efficacy in the treatment of STEMI since it can reduce myocardial injury,improve cardiac function and vascular endothelial function and decrease the incidence of MACE.Therefore,it has a certain clinical application prospect.
Acute ST segment elevation myocardial infarctionGuanxinning tabletHeart functionEndothelial function of blood vesselSafety
维普
万方数据
